Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1233 • ACR Convergence 2020
Use of Multi-Biomarker Disease Activity Scores to Compare Biosimilar Adalimumab-afzb (PF-06410293) with EU-Sourced Reference Adalimumab in a Phase 3, Randomized, Double-Blind Trial in Patients with Active RA
Jonathan Kay¹, Amy Bock², Noriko Iikuni³, Wuyan Zhang⁴ and Daniel Alvarez⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Pfizer, Cambridge, MA, ³Pfizer, New York, NY, ⁴Pfizer, New York, ⁵Pfizer, Collegeville, PA
Background/Purpose: Traditional efficacy endpoints of disease activity (DA) in studies of anti-rheumatic drugs can be confounded by subjective (patient-/physician-reported) assessments, comorbidities, and pre-existing joint damage.…
Abstract Number: 1445 • ACR Convergence 2020
Citrulline Reactive B Cells Are Present in the Lungs of Risk RA and Early Untreated RA
Vijay Joshua¹, Malena Loberg-Haarhaus², Akilan Krishnamurthy¹, Meng Sun³, Christina Gerstner⁴, Aase Hensvold⁵, Khaled Amara¹, Lena Israelsson¹, Ragnhild Stålesen⁶, Bence Rethi⁷, Magnus Sköld⁷, Johan Grunewald¹, Heidi Wähämaa¹, Caroline Grönwall¹, Vivianne Malmström⁸ and Anca Catrina⁵, ¹Karolinska Institutet, Stockholm, Sweden, ²Rheumatology clinic, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ³Karolinska University Hospital and Karolinska Insitutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine,Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, ⁶Karolinska Institute, Stockholm, Sweden, ⁷Karolinska Institutet, Stockholm, ⁸Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: Structural changes, increased tissue citrullination, signs of local inflammation and anti-citrullinated protein autoantibodies (ACPA) are present in the pulmonary compartment of early untreated seropositive…
Abstract Number: 1532 • ACR Convergence 2020
The Non-psychotropic Phytocannabinoids Cannabigerol and Tetrahydrocannabinolic Acid Inhibit Rheumatoid Arthritis Synovial Fibroblast Function by Targeting the Wasabi Receptor TRPA1
Torsten Lowin¹, Matthias Schneider² and Georg Pongratz³, ¹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Düsseldorf, Germany, ²Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany, ³Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, D�sseldorf, Germany
Background/Purpose: While medical cannabis is available for german patients since 2017, its use to alleviate symptoms of rheumatic diseases is not recommended due to a…
Abstract Number: 1595 • ACR Convergence 2020
Using Rheumatoid Arthritis Communication Tool Developed by the RISE Learning Collaborative to Promote Shared Decision-Making
Joad Eseddi¹, Puneet Bajaj², Gabriela Schmajuk³, Jinoos Yazdany⁴ and Salahuddin Kazi⁵, ¹UT Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX, ³University of California, San Francisco, Atherton, CA, ⁴University of California, San Francisco, San Francisco, CA, ⁵Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Patient care is moving from physician directed treatment to a co-design framework that focuses on creating a partnership between patients and physicians. This new…
Abstract Number: 1718 • ACR Convergence 2020
Impact of Treatments on Radiographic Progression over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort
Joanna Kedra¹, David Hajage¹, Alexandre Lafourcade¹, Bernard Combe², Maxime Dougados³ and Bruno Fautrel⁴, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, ²University of Montpellier, Montpellier, France, ³Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁴Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Long-term observational studies on the prediction of structural damage progression (SDP) in rheumatoid arthritis (RA) have mostly considered patients baseline characteristics and have rarely…
Abstract Number: 1734 • ACR Convergence 2020
The Challenge of Assessing Wellbeing from the Patients` Perspective in Early Rheumatoid Arthritis
Diederik De Cock¹, Tianna Poffe², Geert Verbeke², Sofia Pazmino¹, Veerle Stouten¹, Delphine Bertrand¹, Rene Westhovens³ and Patrick Verschueren⁴, ¹KU Leuven, Leuven, Belgium, ²KU Leuven, Leuven, ³University Hospitals Leuven, Belgium, Leuven, Belgium, ⁴University Hospital Leuven, Leuven, Belgium
Background/Purpose: Although more effective therapeutics and treatment strategies for Rheumatoid Arthritis (RA) have improved many patient-reported outcomes (PROs), still a sizeable number of patients in…
Abstract Number: 1752 • ACR Convergence 2020
Prediction of Responder and Non-responder to JAK Inhibitors in Patients with Rheumatoid Arthritis: A Pilot Study with Integrative Cluster Analysis
Masanari Sugawara¹, Yuichiro Fujieda², Atsushi Noguchi³, Shun Tanimura⁴, Yuka Shimizu⁵, Ikuma Nakagawa⁶, Hiroki Takahashi⁷, Michihito Kono⁸, Masaru Kato², Kenji Oku², Olga Amengual² and Tatsuya Atsumi⁹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo city, Hokkaido, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ³Department of Internal Medicine and General Medicine, Japanese Red Cross Kitami Hospital, Sapporo, Japan, ⁴Department of Internal Medicine, Tomakomai City Hospital, Tomakomai, Hokkaido, Japan, ⁵3rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Sapporo, Japan, ⁶Department of Internal Medicine, Takikawa Municipal Hospital, Sapporo, Japan, ⁷Department of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan, ⁸Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine and Faculty of Medicine, Hokkaido University, Sapporo, Japan, ⁹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose: [Background]Oral Janus kinase inhibitors (JAKi) show dramatical efficacy to reduce the disease activity in patients with rheumatoid arthritis (RA). However, there remain some　patients who…
Abstract Number: 1781 • ACR Convergence 2020
Pregnancy After Bariatric Surgery in Women with Rheumatic Diseases and Association with Adverse Birth Outcomes
Namrata Singh¹, Rebecca Baer², Maya Swaminathan³, Shireesh Saurabh⁴, Jeffrey Sparks⁵, Gretchen Bandoli⁶, Elena Flowers⁷, Laura Jelliffe-Pawlowski² and Kelli Ryckman⁸, ¹University of Washington, Bellevue, WA, ²University of California San Francisco, San Francisco, ³University of Washington, Seattle, WA, ⁴Kaiser Permanente WA, Bellevue, WA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶University of California San Diego, La Jolla, CA, ⁷UCSF, San Francisco, CA, ⁸University of Iowa, Iowa City
Background/Purpose: Autoimmune rheumatic diseases (ARD) and bariatric surgery are each risk factors for adverse birth outcomes. To date, no study has investigated their combined impact…
Abstract Number: 1994 • ACR Convergence 2020
Rheumatoid Arthritis Improvement After Exposure to an Anti-Inflammatory “ITIS” Diet Is Associated with Changes of Gut Microbiome and Systemic Metabolome
Roxana Coras¹, Cameron Martino², Julia Gauglitz³, Anupriya Tripathi³, Alan Jarmusch⁴, Francesca Cedola⁵, Marta Fernandez Bustamante⁶, Meritxall Agustín-Perez⁷, Maram Alharthi⁸, Susan Lee⁸, Abha Singh⁸, Soo In Choi⁸, Tania Rivera⁸, Katherine Nguyen⁸, Tatyana Shekhtman⁹, Tiffany Holt¹⁰, Shahrokh Golshan¹¹, Rob Knight³, Pieter Dorrestein¹² and Monica Guma¹³, ¹University of California San Diego, La Jolla, CA, ²Bioinformatics and Systems Biology, University of California San Diego, San Diego, ³University of California San Diego, San Diego, ⁴Univesity of California San Diego, San Diego, ⁵Hospital Policlinico Tor Vergata, Rome, Italy, ⁶Departement of Medicine, Division of Rheumatology, University of California San Diego, San Diego, ⁷Department of Medicine, University of California San Diego, San Diego, San Diego, ⁸Department of Medicine, Division of Rheumatology, University of California San Diego, San Diego, ⁹Department of Psychiatry, University of California, San Diego, San Diego, ¹⁰Center for Integrative Nutrition, University of California San Diego, San Diego, ¹¹Department of Psychiatry, University of California San Diego, San Diego, CA, USA, San Diego, ¹²Department of Pharmacology and Pediatrics, University of California San Deigo, San Diego, ¹³Division of Rheumatology, University of California San Diego, Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: A new dimension has been added to the link between diet and health, the gut microbiome. Of particular interest is the influence of diet…
Abstract Number: 2011 • ACR Convergence 2020
Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study
Evgeny Nasonov¹, Saeed Fatenejad², Mariana Ivanova³, Diana Krechikova⁴, Sofia Kuzkina⁵, Alexey Maslyanskiy⁶, Tatiana Plaksina⁷, Mikhail Samsonov⁵, Marina Stanislav¹, Tamara Tyabut⁸, Irina Vinogradova⁹, Sergey Yakushin¹⁰, Elena Zonova¹¹ and Mark Genovese¹², ¹FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova", Moscow, Russia, ²SFC Medica, LLC, Charlotte, NC, ³UMHAT St. Ivan Rilski, Clinic of Rheumatology, Sofia, Bulgaria, ⁴Non-governmental Healthcare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways"”, Smolensk, Russia, ⁵JSC “R-Pharm”, Moscow, Russia, ⁶SBHI "North-West Federal Medical Research Center n.a. V.A.Almazov", Saint Petersburg, Russia, ⁷SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a. P.A.Semashko", Nizhny Novgorod, Russia, ⁸Belarusian Medical Academy of Postgraduate Education, Minsk, Russia, ⁹Ulyanovsk Regional Clinical Hospital, Ulyanovsk, Russia, ¹⁰Ryazan State Medical University, Ryazan, Russia, ¹¹Novosibirsk State Medical University, State Clinical Polyclinic, Novosibirsk, Russia, ¹²Stanford University Medical Center, Palo Alto, CA
Background/Purpose: We previously reported positive efficacy and safety results of olokizumab (OKZ), an interleukin-6-inhibitor, in patients with RA inadequately controlled by MTX (NCT02760368; CREDO-1) [Nasonov…
Abstract Number: L11 • 2019 ACR/ARP Annual Meeting
Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka ², Vivian Bykerk ³, Thomas W.J. Huizinga ⁴, Gustavo Citera ⁵, Clifton Bingham ⁶, Subhashis Banerjee ⁷, Benjamin Soule ⁸, Marleen Nys ⁹, Sean Connolly ¹⁰, Robert Wong ¹⁰, Kuan-Hsiang Gary Huang ⁷ and Roy Fleischmann ¹¹, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Hospital for Special Surgery, New York City, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁶Johns Hopkins University, Baltimore, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Bristol-Myers Squibb, Princeton, New Jersey, ⁹Bristol-Myers Squibb, Braine L'Alleud, Belgium, ¹⁰Bristol-Myers Squibb, Princeton, ¹¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…
Abstract Number: 38 • 2019 ACR/ARP Annual Meeting
Autophagy Receptor Optineurin in Synovial Fibroblasts Plays a Protective Role Against Joint Destruction in Rheumatoid Arthritis
Wen Shi Lee¹, Masaru Kato ¹, Eri Sugawara ¹, Michihiro Kono ¹, Yuki Kudo ², Michihito Kono ³, Yuichiro Fujieda ¹, Toshiyuki Bohgaki ¹, Olga Amengual ¹, Kenji Oku ¹, Shinsuke Yasuda ¹ and Tatsuya Atsumi ⁴, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Hokkaido University Graduate School of Medicine, Sapporo, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ⁴Hokkaido University, Sapporo, Japan
Background/Purpose: Joint destructions progress throughout the course of rheumatoid arthritis (RA) without complete remission. Optineurin (OPTN) is an autophagy receptor with multiple functions related to…
Abstract Number: 517 • 2019 ACR/ARP Annual Meeting
A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Mark Genovese¹, Kurt de Vlam ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, Iyabode Tiamiyu ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, David Walker ⁶, Tsutomu Takeuchi ⁷ and Kenneth Kalunian ⁸, ¹Stanford University, Stanford, CA, ²Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Northumbria Healthcare, Northumbria, United Kingdom, ⁷Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁸Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA
Background/Purpose: There is an unmet medical need to treat RA in patients who have failed prior biologic DMARD treatments (biologic DMARD inadequate response; bDMARD-IR), some…
Abstract Number: 928 • 2019 ACR/ARP Annual Meeting
Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks
Ronald van Vollenhoven¹, Tsutomu Takeuchi ², Aileen Pangan ³, Alan Friedman ³, Su Chen ³, Maureen Rischmueller ⁴, Ricardo Blanco ⁵, Ricardo Machado Xavier ⁶ and Vibeke Strand ⁷, ¹Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²Keio University School of Medicine, Tokyo, Japan, ³AbbVie Inc., North Chicago, ⁴Department of Rheumatology, The Queen Elizabeth Hospital and University of Adelaide, South Australia, Australia, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ⁶Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ⁷Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Upadacitinib (UPA), a JAK1-selective inhibitor, was efficacious as monotherapy upto 24 weeks (wks) in MTX-naive patients (pts) with active RA.1 To assess safety and efficacy…
Abstract Number: 1332 • 2019 ACR/ARP Annual Meeting
United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization
Sergio Schwartzman¹, Aaron Broadwell ², Alan Kivitz ³, Shawn Black ⁴, Stephen Xu ⁵ and Shelly Kafka ⁶, ¹The Hospital for Special Surgery, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY, ²Rheumatology and Osteoporosis Specialists, Shreveport, LA, USA, Shreveport, LA, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, RI, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].